|
Abstract
|
Background and Aim: MDM4, a negative regulator of the p53 tumor suppression pathway, has been demonstrated
to be overexpressed in a variety of human cancers. Research has revealed that the rs4245739 A>C polymorphism of
MDM4 in the 3′-untranslated region makes it a miR-191 target site, leading to lower MDM4 expression. This study
aimed to detect if the rs4245739 single nucleotide polymorphism (SNP) impacts on thyroid cancer (TC) development
in Iranian-Azeri patients. Materials and Method: Blood samples were taken from 232 healthy controls and 130 TC
patients of Iranian-Azeri ethnicity. For genotyping, Tetra-ARMS PCR was performed. SPSS for Windows (version
22.0, IBM SPSS Inc., USA) and the SHEsis online software were used for data analysis. Results: Alleles of MDM4
rs4245739 SNP demonstrated no significant different in frequencies between patients and controls (p>0.05). Additionally,
genotypes of MDM4 rs4245739 SNP did not increase or decrease TC risk in patients compared with healthy subjects.
Conclusion: Considering the lack of any observed association between the MDM4 rs4245739 polymorphism and TC,
we conclude no significant role in the pathophysiology of the disease.
|